Valneva Expands Chikungunya Vaccine Access, Submits Label Extensions For IXCHIQ To EMA And Health Canada
Portfolio Pulse from Benzinga Newsdesk
Valneva is expanding access to its Chikungunya vaccine by submitting label extensions to the EMA and Health Canada, potentially including adolescents and extending antibody persistence to two years. The company is also seeking marketing authorization in Brazil and expanding its partnership with CEPI to support access in LMICs.
September 18, 2024 | 5:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Valneva is actively working to expand the market for its Chikungunya vaccine by seeking regulatory approvals and partnerships, which could boost sales and market presence.
Valneva's efforts to expand the Chikungunya vaccine's label and access, including regulatory submissions and partnerships, indicate a strategic push to increase market share and sales. This is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90